Skip to main content

Peer Review reports

From: Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Original Submission
9 May 2019 Submitted Original manuscript
30 Sep 2019 Author responded Author comments - Anne Julienne Genuino
5 Jul 2019 Reviewed Reviewer Report - Jon Karnon
5 Aug 2019 Reviewed Reviewer Report - Richard Edlin
Resubmission - Version 2
30 Sep 2019 Submitted Manuscript version 2
31 Oct 2019 Author responded Author comments - Anne Julienne Genuino
Resubmission - Version 3
31 Oct 2019 Submitted Manuscript version 3
Publishing
6 Nov 2019 Editorially accepted
21 Nov 2019 Article published 10.1186/s12913-019-4715-8

You can find further information about peer review here.

Back to article page
\